ARTICLE

Epidemiology

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients

Felix Preisser1,2, Elio Mazzone2,3, Sebastiano Nazzani2,4, Michele Marchioni2,5, Marco Bandini2,3, Zhe Tian2, Fred Saad2, Denis Soulières5, Shahrokh F. Shariat7, Francesco Montorsi3, Hartwig Huland1, Markus Graefen1, Derya Tilki1,8 and Pierre I. Karakiewicz2

BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines provide recommendations for staging of prostate cancer patients in the objective regarding presence of locoregional lymph node metastases (LNM) and bone metastases. We tested the performance characteristics of these recommendations in a community setting.

METHODS: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified patients with available Gleason, clinical stage and prostatic specific antigen. Performance characteristics endpoints consisted of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NVP), overall accuracy and the number needed to image (NNI).

RESULTS: Totally, 191,308 patients were assessable for the validation of the LNM staging recommendations. Sensitivity ranged from 80.6 to 86.3%, specificity from 74.7 to 79.3%, PPV from 7.8 to 8.0%, overall accuracy from 75.0 to 79.3% and NPV was 99.5%. The respective NNI values were 12.5 and 12.8. 197,408 patients were assessable for the validation of bone scan recommendations. These recommendations resulted in 90.8% sensitivity, 76.3% specificity, PPV of 5.7%, NPV of 99.8% and overall accuracy of 76.5%. The NNI was 17.5.

CONCLUSION: The NCCN recommendations for locoregional LNM miss few patients with clinical LNM (0.3–0.4%) and provide a virtually perfect NPV of 99.5%. Also, the recommendations for bone scan miss a marginal number of patients with established bone metastases (0.14%) and yield a virtually perfect NPV of 99.8%.

British Journal of Cancer (2018) 119:1552–1556; https://doi.org/10.1038/s41416-018-0323-3

INTRODUCTION

Clinical staging in the context of prostate cancer (PCa) is important.1 Treatment of individuals with locally advanced or metastatic PCa differs from that for individuals with localised PCa. The distinction between localised PCa vs. locoregional lymph node metastatic PCa and PCa metastatic to bone can be made using the recommendations of the National Comprehensive Cancer Network (NCCN), as outlined in the clinical practice guidelines in oncology.2

Specifically, for staging of patients with suspected locoregional lymph node metastases (LNM) the NCCN PCa guideline (Version 2.2017) recommends a pelvic computed tomography scan (CT) or pelvic magnetic resonance imaging (MRI) if clinical tumour stage is T3 or T4 or in clinical tumour stage T1 when nomogram derived LNM probability is >10%.3

Similarly, for staging of patients with suspected bone metastases, the NCCN PCa guideline recommends a bone scan in clinical tumour stage T1 patients when prostatic specific antigen value (PSA) is >20 ng/ml or if clinical tumour stage is T2 when PSA is >10 ng/ml or if clinical tumour stage is T3 or T4 or if Gleason score is ≥8 or if patients are symptomatic.2

However, to the best of our knowledge these recommendations have never been validated in a community setting within a large epidemiological database, such as the Surveillance, Epidemiology, and End Results (SEER) database. Within the current manuscript, we tested the performance characteristics of the NCCN guidelines regarding presence of locoregional LNM, as well as regarding presence of bone metastases. Specifically, we hypothesised that the use of the NCCN guidelines will not result in more than a marginal proportion of patients with missed locoregional LNM or missed bone metastases.

1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 2Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; 3Department of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; 4Academic Department of Urology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy; 5Department of Urology, SS Annunziata Hospital, “G. D’Annunzio” University of Chieti, Chieti, Italy; 6Centre Hospitalier de l’Université de Montréal, Montreal, Canada; 7Department of Urology, Medical University of Vienna, Vienna, Austria and 8Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Correspondence: Felix Preisser (felixpreisser@gmx.de)

Received: 4 May 2018 Revised: 10 October 2018 Accepted: 11 October 2018
Published online: 14 November 2018

© Cancer Research UK 2018
metastases (M0) were included. These selection criteria resulted in 191,308 assessable patients for testing the NCCN bone scan recommendations. Of 191,308 assessable patients (Tables 1), 2.3% (n = 4,446) had clinical lymph node metastases. Patients with lymph node metastases more frequently had a PSA value > 20 ng/ml (36.7 vs. 7.5%, p < 0.001), more frequently harboured clinical tumour stage T3 to T4 (24.1 vs. 2.3%, p < 0.001) and more frequently harboured GGG 5 (42.5 vs. 6.3%, p < 0.001).

Validation with the use of the Briganti nomogram. Within the use of the Briganti nomogram to predict the LNM probability >10%,

Table 1. SEER-population with prostate cancer for the validation of the bone scan recommendations, stratified according to metastatic status and for the validation of the pelvic CT/MRI recommendations, stratified according to metastatic status and lymph node status

| Study population | Overall (n = 197,408) | Non-metastatic (n = 194,342) (98.4%) | Bone metastatic (n = 3,066) (1.6%) | p Value | Overall (n = 191,308) | Lymph node-negative (n = 186,862) (97.7%) | Lymph node-positive (n = 4,446) (2.3%) | p Value |
|------------------|----------------------|-----------------------------------|----------------------------------|---------|----------------------|------------------------------------------|----------------------------------------|---------|
| **Age**          |                      |                                   |                                  |         |                      |                                          |                                         |         |
| Median (Interquartile range) | 65 (59–71) | 65 (59–71) | 70 (62–77) | <0.001 | 65 (59–71) | 65 (59–71) | 65 (59–70) | <0.001 |
| **Year of diagnosis** | 2011.8 (0.003) | 2011.8 (0.003) | 2012.1 (0.026) | <0.001 | 2011.8 (0.003) | 2011.8 (0.003) | 2012.2 (0.021) | <0.001 |
| **PSA** | 150,991 (76.5) | 150,333 (77.4) | 658 (21.3) | <0.001 | 146,392 (76.5) | 144,669 (77.4) | 1723 (38.8) | <0.001 |
| 10.1–20 | 30,261 (15.3) | 29,615 (15.2) | 646 (21.2) | <0.001 | 29,262 (15.3) | 28,173 (15.1) | 1089 (24.5) | <0.001 |
| >20 | 16,156 (8.2) | 14,394 (7.4) | 1762 (57.5) | <0.001 | 15,654 (8.2) | 14,020 (7.5) | 1634 (36.7) | <0.001 |
| **Clinical tumour stage** |                      |                                   |                                  |         |                      |                                          |                                         |         |
| cT1 | 133,617 (67.7) | 132,434 (68.1) | 1183 (38.6) | <0.001 | 130,790 (68.5) | 129,020 (69.1) | 1770 (39.8) | <0.001 |
| cT2 | 56,131 (28.4) | 55,032 (28.3) | 1099 (35.8) | <0.001 | 54,503 (28.4) | 52,962 (28.3) | 1541 (34.7) | <0.001 |
| ≥cT3 | 5298 (2.7) | 4680 (2.4) | 618 (20.2) | <0.001 | 5336 (2.7) | 4265 (2.3) | 1071 (24.1) | <0.001 |
| Unknown | 2362 (1.2) | 2196 (1.1) | 166 (5.4) | <0.001 | 679 (0.4) | 615 (0.3) | 64 (1.4) | <0.001 |
| **Biopsy Gleason grade group** |                      |                                   |                                  |         |                      |                                          |                                         |         |
| 1 | 86,012 (43.6) | 85,888 (44.2) | 124 (4) | <0.001 | 82,691 (43.2) | 82,523 (44.2) | 168 (3.8) | <0.001 |
| 2 | 53,921 (27.3) | 53,688 (27.6) | 233 (7.6) | <0.001 | 52,570 (27.5) | 51,951 (27.8) | 619 (13.9) | <0.001 |
| 3 | 53,921 (27.3) | 53,688 (27.6) | 233 (7.6) | <0.001 | 52,570 (27.5) | 51,951 (27.8) | 619 (13.9) | <0.001 |
| 4 | 24,697 (12.5) | 24,397 (12.6) | 300 (9.8) | <0.001 | 24,036 (12.6) | 23,315 (12.5) | 721 (16.2) | <0.001 |
| 5 | 18,780 (9.5) | 18,029 (9.3) | 751 (24.5) | <0.001 | 18,293 (9.5) | 17,245 (9.2) | 1048 (23.6) | <0.001 |
| 6 | 13,998 (7.1) | 12,340 (6.3) | 1658 (54.1) | <0.001 | 13,718 (7.2) | 11,828 (6.3) | 1890 (42.5) | <0.001 |

**RESULTS**

NCCN recommendations to perform a pelvic CT or MRI Study population. Of 191,308 assessable patients (Tables 1), 2.3% (n = 4,446) had clinical lymph node metastases. Patients with lymph node metastases more frequently had a PSA value > 20 ng/ml (36.7 vs. 7.5%, p < 0.001), more frequently harboured clinical tumour stage T3 to T4 (24.1 vs. 2.3%, p < 0.001) and more frequently harboured GGG 5 (42.5 vs. 6.3%, p < 0.001).

**PATIENTS AND METHODS**

Study population
Within the SEER database (2004–2014), we identified patients ≤90 years old with available information on Gleason grade group (GGG), clinical tumour stage and PSA value. Patients with a serum PSA value ≥98 ng/ml were excluded.

Testing of the NCCN recommendations
We performed two separate analyses. First, we tested the NCCN guideline recommendations for identification of patients with positive clinical lymph node status (cN1). The NCCN recommends a pelvic CT/MRI if clinical tumour stage is T3 or T4 or if clinical tumour stage is T1 or T2 and the nomogram derived probability of LNM is >10%. Since two different nomograms can be applied and no specific recommendation is made for the use of one vs. the other, we performed two separate analyses. The first analysis relied on the use of the updated Briganti et al. nomogram that includes biopsy core information. The second analysis relied on the use of the online Memorial Sloan Kettering Cancer Center (MSKCC) dynamic prostate cancer nomogram that includes biopsy core information. Only patients with known positive clinical lymph node status (cN1) or negative clinical lymph node status (cN0) were included. These selection criteria resulted in 191,308 assessable patients for testing of the NCCN recommendations.

Second, we tested the NCCN guideline recommendations for identification of patients with bone metastases. The NCCN recommends a bone scan if clinical tumour stage is T1 and PSA > 20 ng/ml or if clinical tumour stage is T2 and PSA > 10 ng/ml or if clinical tumour stage is T3 or T4 or if Gleason Score is ≥8 (GGG ≥ 4). Only patients with known bone metastases (M1b) or without metastases (M0) were included. These selection criteria resulted in 197,408 assessable patients for testing the NCCN bone scan recommendations.

Statistical analyses
Descriptive statistics consisted of frequencies and proportions for categorical variables. Means, medians and ranges were reported for continuously coded variables. The chi-square tested the statistical significance of proportions’ differences. The t test and Kruskal–Wallis test examined the statistical significance of means and medians differences, respectively.

The specific performance characteristics for each of the guideline recommendations consisted of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NVP), overall accuracy and the number needed to image (NNI). Finally, the positive (sensitivity/(1-specificity)) and negative likelihood ratios ((1 − sensitivity)/specificity) for each recommendation were calculated. R software environment for statistical computing and graphics (version 3.4.0) was used for all statistical analyses. All tests were two sided with a level of significance set at p < 0.05.
117,120 assessable patients were identified (Table 2a). Here, a pelvic CT/MRI was not recommended in 91,374 (78.0%) patients. Within those individuals 493 (0.4%) with established locoregional LNM would have been missed. This resulted in a NPV of 99.5%. Conversely, a pelvic CT/MRI was recommended in 25,746 (22.0%) patients. Of those, 23,695 (20.2%) would have been imaged despite harbouring cN0 status. The resulting PPV was 8.0% and the resulting NNI to detect one patient with locoregional LNM was 17.5. When patient stratification according to NCCN pelvic CT/MRI recommendations were assessed according to sensitivity and specificity values, a sensitivity of 80.6% and a specificity of 79.3% were recorded. Finally, the positive and negative likelihood ratios were 3.89 and 0.24, respectively.

**Validation with the use of the MSKCC nomogram.** Within the use of the MSKCC nomogram to predict the LNM probability >10%, 119,502 assessable patients were identified (Table 2b). Here, a pelvic CT/MRI was not recommended in 87,520 (73.2%) patients. Within those individuals 395 (0.3%) did harbour locoregional LNM and would be considered as missed. Similarly, with the use of the online MSKCC nomograms to predict the LNM probability >10%, since no specification within the NCCN guidelines is made with respect to, which nomogram should be used. With the use of the Briganti et al. and online MSKCC LNM nomograms to predict the LNM probability >10%, no significant difference was found. Accordingly, we hypothesised that the use of the MSKCC guidelines would not result in more than a marginal proportion of patients with missed locoregional lymph invasion or missed bone metastases. Our analyses demonstrated several noteworthy findings.

**DISCUSSION**

Staging of patients with PCa provides vital information with respect to clinical decision-making. Confirmation of locoregional LNM affects treatment choice. Similarly, confirmation of bone metastases, also affects treatment assignment. NCCN guidelines have defined criteria for imaging of patients with suspected locoregional LNM.2 Similarly, the NCCN guidelines have also established criteria for imaging of patients in whom bone metastases are suspected.2 However, to the best of our knowledge these recommendations have never been validated in a community setting within a large epidemiological database. Based on this limitation we tested the performance characteristics of these guideline recommendations. Specifically, we hypothesised that the use of the NCCN guidelines will not result in more than a marginal proportion of patients with missed locoregional lymph invasion or missed bone metastases. Our analyses demonstrated several noteworthy findings.

First, regarding the NCCN recommendations to perform a pelvic CT/MRI we tested two different approaches. Specifically, we tested the use of two different ( Briganti et al. and online MSKCC) LNM nomograms to predict the LNM probability >10%, since no specification within the NCCN guidelines is made with respect to, which nomogram should be used. With the use of the Briganti nomogram, 117,120 assessable patients were identified, and a pelvic CT/MRI was not recommended in 91,374 (78.0%) patients. Of those, 493 (0.4%) would have been imaged despite harbouring cN0 status. The resulting PPV was 8.0% and the resulting NNI to detect one patient with bone metastases was 17.5. When patient stratification according to NCCN bone scan recommendations were assessed according to sensitivity and specificity values, a sensitivity of 90.8% and a specificity of 76.3% were recorded. Finally, the positive and negative likelihood ratios were 3.83 and 0.12, respectively.

**Table 2.** Recommendations for pelvic CT/MRI according to the NCCN prostate cancer guidelines, >10% LNM probability predicted a with the use of the Briganti nomogram and b with the use of the online MSKCC nomogram

| Overall population | n = 117,120 | Reference: cN1 stage according to imaging | NNI = 12.5(1/PPV) |
|-------------------|------------|------------------------------------------|-------------------|
| cN1 n = 2544 | 2.2% | FP n = 23,695 (20.2%) | PPV = TP/(TP + FP) 8.0% |
| cN0 n = 114,576 | 97.8% | TN n = 90,881 (77.6%) | NPV = TN/(FN + TN) 99.5% |
| Pelvic CT/MRI recommended = 25,746 | 22.0% | TP n = 2,051 (1.8%) | Sensitivity = TP/(TP + FN) 90.8% |
| Pelvic CT/MRI not recommended = 91,374 | 78.0% | FN n = 493 (0.4%) | Specificity = TN/(FP + TN) 79.3% |
| Sensitivity = TP/(TP + FN) 86.3% | Specificity = TN/(FP + TN) 74.7% | Accuracy = TP + TN/All 75.0% |
| Overall population | n = 119,502 | Reference: cN1 stage according to imaging | NNI = 12.8(1/PPV) |
| Pelvic CT/MRI recommended = 31,982 | 26.8% | TP n = 2,497 (2.1%) | PPV = TP/(TP + FP) 7.8% |
| Pelvic CT/MRI not recommended = 87,520 | 73.2% | FN n = 395 (0.3%) | Specificity = TN/(FP + TN) 99.5% |
| Sensitivity = TP/(TP + FN) 86.3% | Specificity = TN/(FP + TN) 74.7% | Accuracy = TP + TN/All 75.0% |

**NCCN National Comprehensive Cancer Network, CT computer tomography, MRI magnetic resonance imaging, LNM lymph node metastases, TP true positive, FP false positive, FN false negative, TN true negative, NNI number needed to image, PPV positive predictive value, NPV negative predictive value.**
considered as missed instances of LNM. This marginally low number of patients resulted in a virtually perfect NPV of 99.5%, for both nomograms. In consequence, we confirmed that the NCCN guideline recommendations for pelvic lymph node imaging result in only a marginal proportion of omitted instances of imaging, despite the presence of locoregional LNM, regardless of the used nomogram to predict the LNM probability >10%. Based on this observation, the use of the NCCN recommendations for identification of LNM can be safely endorsed in the community setting.

We also examined the guidelines regarding their sensitivity and specificity. Here, a sensitivity of 80.6% with the use of the Briganti et al. nomogram and respectively 86.3% with the use of the MSKCC nomogram was recorded in individuals with established locoregional LNM. Conversely, the specificity with the use of the Briganti et al. nomogram was 79.3% compared to 74.7% with the use of the MSKCC nomogram, in individuals without locoregional LNM. Higher sensitivity of the MSKCC nomogram could be related to the fact that the Briganti nomogram was developed within a European tertiary referral center. Conversely, the MSKCC nomogram originates from an American tertiary care center. Despite these small differences, the performance characteristics recorded for both nomograms indicate an excellent balance between sensitivity and specificity that is expected from a robust testing recommendation. Moreover, the use of both nomograms resulted in similar NNI values, which were, respectively, 12.5 for the Briganti nomogram vs. 12.8 for the MSKCC nomogram. Finally, the positive and negative likelihood ratios with the use of the Briganti vs. the MSKCC nomogram were similar, 3.89 and 0.24 vs. 3.41 and 0.18, respectively. These results demonstrate an acceptable confidence for both nomograms regarding the NCCN recommendations to perform a pelvic CT/MRI. Taken together, our data validate the use of the NCCN guideline recommendations for identification of LNM with either the MSKCC or the Briganti nomogram. The choice of a specific nomogram may be left to the discretion of individual physicians.

Second, regarding the NCCN guideline recommendations for presence of bone metastases, we relied on 197,408 assessable patients. Within those individuals the guidelines did not recommend a bone scan in 148,600 (75.3%) patients. Of those, only 281 or 0.14% did harbour bone metastases and would be recommended a bone scan in 148,600 (75.3%) patients. Of those, 197,408 assessable patients with localised PCa. Additionally, the SEER database does not capture information in regards of symptoms (e.g., bony pains) or laboratory abnormalities (e.g., elevated alkaline phosphatase) and as such, the current study cannot account for cases that might be diagnosed based on this information. Last but not least, both recommendations are based on gold standards that maybe reconsidered. To the best of our knowledge, this is the first report of this kind and further studies are welcome to confirm our results.

Our study is not devoid of limitations. First and foremost, the SEER database only represents approximately 30% of the United States population, which is a limitation for itself. Moreover, the NCCN guidelines do not provide recommendations for abdominal CT/MRI staging and thereby we were not able to include patients with visceral metastases or non-locoregional LNM in our analyses. However, such patients need also be identified and deserve to be studied, since their outcome and treatment differs from those of patients with localised PCa. Additionally, the SEER database does not capture information in regards of symptoms (e.g., bony pains) or laboratory abnormalities (e.g., elevated alkaline phosphatase) and as such, the current study cannot account for cases that might be diagnosed based on this information. Last but not least, both recommendations are based on gold standards that maybe suboptimal. Specifically, bone scans have recently been shown to miss bone metastases. Similarly, pelvic CT/MRI have recently been shown to miss locoregional LNM. In consequence, future gold standards will need to be reassessed. However, to date only studies with very limited sample sizes are available, when new gold standards such as prostate specific membrane antigen scans are compared to routine imaging. In consequence, population-based studies relying on prostate specific membrane antigen-based testing

---

**Table 3. Recommendations for bone scan according to the NCCN prostate cancer guidelines**

| Overall population n = 197,408 | Reference: M1b stage according to imaging | NNI = 17.5/(1/PPV) |
|-------------------------------|------------------------------------------|--------------------|
| M1b n = 3066 (1.55%)          | M0 n = 194,342 (98.45%)                 |                    |
| Bone scan recommended n = 48,808 (24.7%) | TP n = 2785(1.41%) | FP n = 46,023(23.32%) | PPV = TP/(TP + FP) 5.7% |
| Bone scan not recommended n = 148,600 (75.3%) | FN n = 281(0.14%) | TN n = 148,319(75.13%) | NPV = TN/(TN + FN) 99.8% |
| Sensitivity = TP/(TP + FN) 90.8% | Specificity = TN/(FP + TN) 76.3% | Accuracy = TP + TN/All 76.5% |
cannot yet be performed. Limited availability of prostate specific membrane antigen testing will persist for next several years and will hamper such efforts for at least next decades.

CONCLUSION
The NCCN based recommendation for locoregional LNM miss very few patients with clinical LNM (0.3–0.4%), regardless of the applied methodology and provide a virtually perfect NPV of 99.5% and acceptable negative likelihood ratios (0.18–0.24). The NCCN bone scan recommendations also miss a marginal number of patients with established bone metastases (0.14%) and yield a virtually perfect NPV of 99.8% and a very acceptable negative likelihood ratio of 0.12. In consequence, both NCCN recommendations may be safely endorsed in clinical practice.

ACKNOWLEDGEMENTS
The protocol for the research project has been approved by the institutional review board and it conforms to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013).

AUTHOR CONTRIBUTIONS
F. Preisser: conceptualisation, writing—original draft, formal analysis and validation. E. Mazzone: writing—original draft, visualisation. S. Nazzani: formal analysis, visualisation. M. Marchioni: methodology, data curation. M. Bandini: visualisation, writing—review and editing. Z. Tian: methodology, software, resources. F. Saad: writing—review and editing. D. Soulières: writing—review and editing. S.F. Shariat: validation, review and editing. D. Tilki: supervision, project administration. P. I. Karakiewicz: project administration, supervision, conceptualisation, writing—original draft.

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

Availability of data and materials: SEER data is available for purchase at https://seer.cancer.gov.

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

REFERENCES
1. Shukla, M. E. et al. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database. Clin. Genitourin. Cancer 13, 17–21 (2015).
2. Mohler J. L., et al. NCCN clinical practice guidelines in oncology: prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2017).
3. Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur. Urol. 69, 428–435 (2016).
4. Chun, F. K. et al. Development and external validation of an extended 10-core biopsy nomogram. Eur. Urol. 52, 436–444 (2007).
5. Briganti, A. et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur. Urol. 61, 480–487 (2012).
6. Chun, F. K. et al. Development and external validation of an extended repeat biopsy nomogram. J. Urol. 177, 510–515 (2007).
7. Merdan, S. et al. Toward better use of bone scans among men with early-stage prostate cancer. Urology 84, 793–798 (2014).
8. Briganti, A. et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur. Urol. 57, 551–558 (2010).
9. Bandini M., et al. Contemporary trends and survival outcomes after aborted radical prostatectomy in lymph node metastatic prostate cancer patients. Eur. Urol. Focus. https://doi.org/10.1016/j.euf.2018.01.009 2018.
10. Rhee, H. et al. Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. J. Urol. 196, 1261–1267 (2016).
11. Bjurlin M. A., et al. Imaging the high-risk prostate cancer patient: current and future approaches to staging. Urology 116 3–12 2018.
12. Lavalaye, J., Kaldeway, P. & van Melick, H. H. Diffuse bone metastases on (68)Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan. Eur. J. Nucl. Med. Mol. Imaging 43, 1563–1564 (2016).
13. Rathke H., et al. Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer. J. Nucl. Med. 59, 1373–1379 2018.
14. Budaus, L. et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur. Urol. 69, 393–396 (2016).
15. Maurer, T. et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J. Urol. 195, 1436–1443 (2016).
16. Rauscher, I. et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J. Nucl. Med. 57, 1713–1719 (2016).